Setting Standards Empowering Research Building Shareholder Value
First Quarter 2025 Financial Results May 6th 2025
CEO Commentary
MICHAEL EGHOLM, PHD
3
Executing on Our Vision
Building a Diversified Life Science Tools Industry Leader
Revenue: $40.8 million in Q1 2025
Clean Balance Sheet: $261 million in cash3 provides path to adj EBITDA + expected in 2026
Cost Reductions: Operationalized ~$10 million in Q1 2025 totaling to $90 million since merger
Strategic Growth: New proteomics solutions, Illumina NGS rollout and targeted M&A
Profitability Metrics: 22% non-GAAP OpEx1 and
29% adjusted EBITDA improvements2 YoY
2025 Outlook: Targeting revenue in the range of$165 million to $175 million4
1Refer to Appendix for a reconciliation between GAAP and non-GAAP OpEx.
2 Refer to appendix for reconciliation between net loss and adjusted EBITDA. .
3 Cash , cash equivalents, restricted cash, and short-term investments as of March 31, 2025.
4 Outlook assumes a high single-digit millions decline in our Americas academic revenue due to anticipated NIH funding pressures, no expected effect from U.S. export controls and limited impact 4
from tariffs.
Leverage Standard BioTools Business System (SBS) Flywheel to Deliver Value
APPLYING SBS TO DRIVE IMPROVEMENT
Identify high-value solutions capable of lifting off from prior years of costly R&D investments
Leverage SBS to improve quality, increase customer satisfaction and profitability
Deliver quality improvement & cost saving opportunities to drive better customer outcomes post-acquisition
CLEAR STRATEGY
New Asset
FOCUS ON THE CRITICAL FEW
KEY FINANICIAL METRICS
22% reduction in 1Q25 non-GAAP operating expenses1
45% reduction in 1Q25 operating loss
29% improvement in 1Q25 adjusted EBITDA2
LEAN TRANSFORMATION
2 Refer to Appendix for a reconciliation between net loss and adjusted EBITDA.
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |